Local tumour control and radiation side effects for fractionated stereotactic photon beam radiotherapy compared to proton beam radiotherapy in uveal melanoma

• Published in: Radiotherapy and oncology Vol. 157; pp. 219 - 224
• Main Authors: van Beek, Jackelien G.M., Ramdas, Wishal D., Angi, Martina, van Rij, Caroline M., Naus, Nicole C., Kacperek, Andrzej, Errington, Roger D., Damato, Bertil, Heimann, Heinrich, Kiliç, Emine
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.04.2021
• Subjects: Eye Enucleation; Fractionated stereotactic photon beam radiotherapy; Humans; Local tumour control; Melanoma - radiotherapy; Neoplasm Recurrence, Local; Netherlands; Proton beam radiotherapy; Protons; Radiosurgery; Retrospective Studies; Side effects; United Kingdom; Uveal melanoma; Uveal Neoplasms - radiotherapy; United Kingdom; Netherlands; Uveal melanoma; Side effects; Proton beam radiotherapy; Fractionated stereotactic photon beam radiotherapy; Local tumour control
• ISSN: 0167-8140; 1879-0887
• DOI: 10.1016/j.radonc.2021.01.030

•Uveal melanoma treated with stereotactic radiotherapy: 5-year tumour control 96.1%.•Uveal melanoma treated with proton beam radiotherapy: 5-year tumour control 96.1%.•Vitreous haemorrhages occur more after stereotactic radiotherapy than proton beam.•Larger tumours are a risk for maculopathy and enucleation. To compare the adverse side effects of fractionated stereotactic photon beam radiotherapy (fSRT) with proton beam radiotherapy (PBR) in patients with uveal melanoma (UM). A retrospective study investigating 306 UM patients treated with fSRT (N=153) by the Rotterdam Ocular Melanoma Study group (ROMS), The Netherlands, between 1999–2014 or with PBR (N=153) at the Royal Liverpool University Hospital and the Clatterbridge Cancer Centre, Bebington, United Kingdom, between 1993–2014. The tumours treated with fSRT were matched with tumours treated with PBR based on sex, left or right eye, TNM classification, posterior margin ≤ or > 3mm of the fovea and of the optic disc. The five-year actuarial rates of tumour recurrence were 4.5% for fSRT and 6.1% for PBR. For fSRT and PBR, the five-year actuarial rates of maculopathy were 14.9% and 12.4%, and for vitreous haemorrhage were 29.4% and 4.7%, respectively. Only vitreous haemorrhage (HR: 0.19, 95% CI: 0.07–0.56) was more common after fSRT compared to PBR. Overall, larger tumours were risk factors for maculopathy and secondary enucleation. Both treatments have excellent local tumour control. In matched groups, vitreous haemorrhage was the only adverse side effect showing a significant difference between groups.